Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Galirayo who wrote (20100)	11/6/2006 3:48:03 PM
From: Jibacoa	Read Replies (1) \| Respond to of 23958

I'm not that good at targets. I think that must be my ONLY Weakness. lol How about resistance instead of target Can you make a better guess at that ? <g> bigcharts.marketwatch.com bigcharts.marketwatch.com Now this is an easier question: Do you think LMRA will make it to 10 this week ? <g> bigcharts.marketwatch.com

To: Galirayo who wrote (20100)	11/6/2006 4:14:24 PM
From: ACAN	Respond to of 23958

Ray; [XOMA} XOMA Successfully Completes Initial $15 Million BioDefense Contract with NIAID Monday November 6, 3:47 pm ET Project Completed On Time and On Budget BERKELEY, Calif.--(BUSINESS WIRE)--XOMA Ltd. (Nasdaq:XOMA - News) today announced that it has received final acceptance from the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH), of all deliverables under Contract No. HHSN266200500004C. This $15 million contract with NIAID was awarded to XOMA in March of 2005 to develop manufacturing processes for three anti-botulinum neurotoxin monoclonal antibodies. ADVERTISEMENT With the completion of this first contract, XOMA has created production cell lines using its proprietary antibody expression systems, built and qualified master and manufacturer's working cell banks, developed production processes and produced initial cGMP quantities of the three antibodies. "XOMA's expertise at developing therapeutic monoclonal antibodies was tangibly demonstrated in our performance on this contract, as was our ability to successfully provide all deliverables on time and on budget," said John L. Castello, chairman of the board, president, and chief executive officer of XOMA. We expect to continue performing at this level on the $16 million follow-on contract we announced on July 31, and we believe XOMA is well positioned to continue supporting the U.S. Government's critical biodefense initiatives." Allan

To: Galirayo who wrote (20100)	11/6/2006 4:19:06 PM
From: ACAN	Respond to of 23958

Ray; [SONS] Sonus Achieves Record Quarter with Strong Revenue Growth; Company Provides Update on Voluntary Review of Historical Stock Option Grant Practices CHELMSFORD, Mass., Nov. 6 /PRNewswire-FirstCall/ -- Sonus Networks, Inc. (Nasdaq: SONS - News), a leading supplier of service provider Voice over IP (VoIP) infrastructure solutions, today reported its revenue results for the third quarter ended September 30, 2006. The Company also reported that its Audit Committee has completed the previously announced voluntary review of the Company's practices with respect to historical employee stock option grants since its Initial Public Offering (IPO) and, based on its preliminary evaluation of the accounting impact of this review, the Company has determined that it will restate its historical financial statements to make any necessary accounting adjustments. ADVERTISEMENT Revenues for the third quarter of fiscal 2006 were $75 million. Cash, cash equivalents and investments increased by $27 million during the third quarter of 2006 and by $21 million year-over-year to $346 million. Allan

To: Galirayo who wrote (20100)	11/6/2006 8:17:03 PM
From: ACAN	Read Replies (2) \| Respond to of 23958

Ray' [HSR] looks like it has set in a 10down and a reversal may be in the works, also [OTD] is setting in a bottom. Allan